Novartis AG Company Profile (VTX:NOVN)

Novartis AG trades on the VTX under the ticker symbol "NOVN."

14 equities research analysts have issued 1-year price objectives for Novartis AG's shares. Their forecasts range from CHF 75 to CHF 97. On average, they expect Novartis AG's share price to reach CHF 85.50 in the next year. View Analyst Ratings for Novartis AG.

Some companies that are related to Novartis AG include ABB (ABBN), Actelion Ltd (ATLN), Compagnie Financiere Richemont SA (CFR), Lafargeholcim Ltd (LHN), Nestle SA (NESN), Roche Holding (ROG), SGS SA (SGSN), Swiss Re AG (SREN), UBS Group AG (UBSG) and Zurich Insurance Group AG (ZURN).

Novartis AG's management team includes the folowing people:

• Joseph S. Jimenez, Chief Executive Officer, Member of the Executive Committee
• Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
• Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
• James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
• Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee
• Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
• Bruno Strigini, Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
• Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee
• Steven Baert, Head of Human Resources, Member of the Executive Committee
• Vasant Narasimhan M.D., Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee